Prescription change from cinacalcet hydrochloride to evocalcet in hemodialysis patients
Not Applicable
- Conditions
- Chronic hemodialysis patients with secondary hyperparathyroidism
- Registration Number
- JPRN-UMIN000036702
- Lead Sponsor
- Kidney Disease and Dialysis Center, Hidaka Hospital, Hidaka-kai
- Brief Summary
PTH increased for several months, while Ca transiently increased. The cinacalcet dose just before the switch was positively correlated with change in the amplitudes of PTH and Ca. The change in the amplitude of PTH was positively correlated with the change in the amplitude of Ca, suggesting that the transient Ca elevation was derived from the bone. Some patients stopped taking drugs that stimulate GI motility. The proportion of patients with GI symptoms decreased and medication adherence increased.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 147
Inclusion Criteria
Not provided
Exclusion Criteria
Patients not treated with cinacalcet hydrochloride Patients without informed consent
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum parathyroid hormone (PTH) levels for 12 months after the switching.
- Secondary Outcome Measures
Name Time Method Evocalcet dose Serum corrected calcium levels Serum phosphate levels Serum alkaline phosphatase levels Questionnaire on GI symptoms and medication adherence Concomitant medication